Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Erdafitinib in Hepatic Impairment
NCT03587363Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of erdafitinib in urothelial carcinoma (UC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 21 days, Time to Reach Maximum Observed Plasma Concentration at 21 days and 4 more. Started Dec 2018; status: terminated.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03587363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587363.